TLDR
- JPMorgan raised its UNH price target to $466 from $420, keeping an “overweight” rating
- Mizuho also lifted its target to $460 from $440 with an “outperform” rating
- UNH hit a new 52-week high of ~$413 on June 9, up over 20% in 2026
- Q1 2026 earnings beat estimates with revenue of $111.7B and EPS of $7.23
- Medical care ratio improved to 83.9% from 84.8%, signaling better profitability
UnitedHealth Group (UNH) closed at $407.73 on June 10, pulling back 1.28% on the day, but still sitting near its 52-week high after a wave of analyst upgrades earlier in the week.
UnitedHealth Group Incorporated, UNH
On June 8, JPMorgan raised its price target on UNH to $466 from $420, keeping an “overweight” rating. That’s now the highest target on the Street, sitting roughly 14% above where the stock was trading at the time.
Within the same hour, Mizuho followed with its own lift — raising its target to $460 from $440 and maintaining an “outperform” rating.
Mizuho told clients that the managed care sector is moving into a calmer policy stretch. Surprise rule changes out of Washington have been easing off after three rough years, and that backdrop matters.
The stock hit a fresh 52-week high of around $413 on June 9, up more than 20% so far in 2026.
A Rough 2025 Set the Stage
To understand why analysts are this bullish now, you have to remember how bad things got last year.
In May 2025, CEO Andrew Witty stepped down unexpectedly. The board brought back former chief Stephen Hemsley. The company suspended its 2025 outlook as medical costs ran above plan.
On top of that, the Justice Department opened a review of UnitedHealth’s Medicare billing practices. That review remains open.
Wall Street responded by dumping the stock. UNH fell to roughly $300–$312 a share — down from its all-time closing high of $603.20 in November 2024. Berkshire Hathaway bought in near $271 during the dip, then sold the entire position in Q1 2026.
What Changed in 2026
Q1 2026 earnings did the heavy lifting. UnitedHealth posted revenue of $111.7 billion and adjusted EPS of $7.23, both above estimates. The stock jumped more than 8% on the report.
The number that really moved the needle was the medical care ratio — the share of each premium dollar paid out in claims. It dropped to 83.9% from 84.8% a year earlier. When that number falls, the company keeps more revenue as profit. That improvement rebuilt Wall Street confidence faster than any management commentary could.
The Zacks consensus for Q2 stands at $4.84 EPS and $110.05 billion in revenue. Full-year estimates sit at $18.32 EPS and $443.7 billion in revenue, implying roughly 12% earnings growth year over year.
UNH currently trades at a forward P/E of 22.55, ahead of the industry average of 19.11.
The JPMorgan bull case hinges on three things going right: the DOJ Medicare review wrapping up without major financial penalties, medical costs continuing to fall, and management delivering on its 13%–16% long-term growth target.
Berkshire’s exit — selling a stock it bought near the lows, quickly — is one data point some investors are watching.
The Medical-HMOs industry currently holds a Zacks Industry Rank of 25, placing it in the top 11% of all tracked industries.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
